Drugmakers, whose industry pricing faced renewed scornthis month from President Donald Trump, have been taking advantage of the U.S. tax overhaul he signed last year to buy back shares of their own underperforming stocks.
Biopharma Deploy Trump’s Tax Windfall to Buy Back Billions in Stock
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться